Regional, Artery-Specific Thresholds of Quantitative Myocardial Perfusion by PET Associated with Reduced Myocardial Infarction and Death After Revascularization in Stable Coronary Artery Disease

K. Lance Gould 1, Nils P. Johnson 1, Amanda E. Roby 1, Tung Nguyen 1, Richard Kerkreekide 1, Mary Haynie 1, Dejian Lai 2, Hongjian Zhu 2, Monica B. Patel 1, Richard Smalling 3, Sal Arain 3, Prakash Balan 3, Tom Nguyen 4, Anthony Estrera 4, Stefano Sdringola 1, Mohammad Majdidi 1, Angelo Nascimbene 5, Pranav Loyalka 5, Biswajit Kar 5, Igor Gregoric 5, Hazem Safi 5, and David McPherson 5

1 Division of Cardiology, Department of Medicine, McGovern Medical School, Weatherhead PET Center for Preventing and Reversing Atherosclerosis, University of Texas Health Science Center and Memorial Hermann Hospital, Houston, Texas; 2 Department of Biostatistics and Data Science, School of Public Health, University of Texas Health Science Center, Houston Texas; 3 Division of Cardiology, Department of Medicine, McGovern Medical School, University of Texas Health Science Center and Memorial Hermann Hospital, Houston, Texas; 4 Department of Cardiothoracic Vascular Surgery, McGovern Medical School, University of Texas Health Science Center and Memorial Hermann Hospital, Houston, Texas; and 5 Department of Advanced Cardiopulmonary Therapies and Transplantation, McGovern Medical School, University of Texas Health Science Center at Houston and Memorial Hermann Hospital, Houston, Texas

See an invited perspective on this article on page 407.

Because randomized coronary revascularization trials in stable coronary artery disease (CAD) have shown no reduced myocardial infarction (MI) or mortality, the threshold of quantitative myocardial perfusion severity was analyzed for association with reduced death, MI, or stroke after revascularization within 90 d after PET. Methods: In a prospective long-term cohort of stable CAD, regional, artery-specific, quantitative myocardial perfusion by PET, coronary revascularization within 90 d after PET, and all-cause death, MI, and stroke (DMS) at 9-y follow-up (mean ± SD, 3.0 ± 2.3 y) were analyzed by multivariate Cox regression models and propensity analysis. Results: For 3,774 sequential rest–stress PET scans, regional, artery-specific, severely reduced coronary flow capacity (CFC) (coronary flow reserve ≤ 1.27 and stress perfusion ≤ 0.83 cc/min/g) associated with 60% increased hazard ratio for major adverse cardiovascular events and 30% increased hazard of DMS that was significantly reduced by 54% associated with revascularization within 90 d after PET (P = 0.0389), compared with moderate or mild CFC, coronary flow reserve, other PET metrics or medical treatment alone. Depending on severity threshold for statistical certainty, up to 19% of this clinical cohort had CFC severity associated with reduced DMS after revascularization. Conclusion: CFC by PET provides objective, regional, artery-specific, size–severity physiologic quantification of CAD severity associated with high risk of DMS that is significantly reduced after revascularization within 90 d after PET, an association not seen for moderate to mild perfusion abnormalities or medical treatment alone.

Key Words: quantitative myocardial perfusion; coronary revascularization; cardiac PET

J Nucl Med 2019; 60:410–417
DOI: 10.2967/jnumed.118.211953

C

Cardiac PET remains underutilized despite being the gold standard for quantitative myocardial perfusion to define physiologically severity of coronary artery disease (CAD). Indeed, the current invasive standard for physiologic stenosis severity, fractional flow reserve (FFR), driven by the FAME trial (1), was validated by comparison to quantitative PET (2). Consequently, for a large, prospective, real-world, clinical cohort over long-term follow-up, we asked what artery-specific severity threshold of quantitative perfusion associates with reduced death or myocardial infarction (MI) with and without revascularization in stable CAD.

MATERIALS AND METHODS

The Weatherhead PET Center for Preventing and Reversing Atherosclerosis, McGovern Medical School, University of Texas Health Science Center at Houston, obtained 5,373 routine diagnostic rest–stress, quantitative, myocardial perfusion PET scans on sequential patients of the authors, referrals by other physicians, and self-referred patients with or at risk of CAD. All subjects signed a written informed consent form for PET and follow-up as approved by the institutional Committee for the Protection of Human Subjects. Complete detailed medical history, all tests, and procedures were obtained at each PET and entered into a dedicated medical record database.

For this study, PET scans were excluded for the following reasons: 374 due to attention-deficit/hyperactivity disorder medications or measured blood caffeine that inhibit vasodilator stress, 312 due to nonstandard stress protocols used in other published research, 40 due to technical failures (0.7%), and 873 due to a long-term event-free follow-up of
| Characteristic, # and % of group | Yes | SD or % | No | SD or % | P |
|---------------------------------|-----|---------|----|---------|---|
| Total (n = 3,774)               | 134 | 3.60%   | 3,640 | 96.40% | <0.00001 |
| Age (y)                         | 66.2 ± 9.9 | 62.0 ± 11.9 | 0.001 |
| Body mass index                 | 28.5 ± 4.2 | 28.0 ± 4.4 | 0.173 |
| Male, # and % of total          | 116 | 87%     | 2,694 | 74%    | 0.001 |
| Prior PCI, # and % of group     | 72  | 54%     | 1,003 | 28%    | <0.00001 |
| Prior CABG, # and % of group    | 28  | 21%     | 437   | 12%    | 0.002 |
| MI in past 3 mo, # and % of group | 6   | 4%      | 42    | 1%     | 0.001 |
| Hypertension, # and % of group  | 103 | 77%     | 2,430 | 67%    | 0.014 |
| Dyslipidemia, # and % of group  | 128 | 96%     | 3,253 | 89%    | 0.022 |
| Diabetes, # and % of group      | 35  | 26%     | 784   | 22%    | 0.206 |
| Past or active smoking, # and % | 41  | 31%     | 1439  | 40%    | 0.037 |
| Medication, # and %             |     |         |       |        |     |
| Statin                          | 115 | 86%     | 2,579 | 71%    | 0.0001 |
| Antiplatelet                    | 119 | 89%     | 2,510 | 69%    | <0.00001 |
| β-blocker                       | 95  | 71%     | 1,556 | 43%    | <0.00001 |
| ACEI or ARB                     | 84  | 63%     | 1,866 | 51%    | 0.009 |
| Calcium channel blocker         | 24  | 18%     | 567   | 16%    | 0.465 |
| Diuretic                        | 40  | 30%     | 868   | 24%    | 0.110 |
| Risk factors only—no history of CAD | 36 | 27%     | 2,100 | 58%    | <0.00001 |
| Known CAD (MI, angiography, revascularization), # and % | 98 | 73% | 1,463 | 40% | <0.00001 |
| Calcium > 120 HU on CT, # % of group | 132 | 99% | 2,748 | 75% | 0.0001 |
| Recent typical angina, # and %  | 59  | 44%     | 262   | 7%     | <0.00001 |
| Recent atypical angina, # % of group | 4  | 3%      | 96    | 3%     | 0.8055 |
| Recent atypical angina, # and % | 63  | 47%     | 358   | 10%    | <0.00001 |
| Angina with vasodilatory stress, # and % | 72 | 54% | 257 | 7% | <0.00001 |
| Stress ST depression > 1 mm, # and % | 14 | 10% | 16 | 0% | <0.00001 |
| Stress EF by ECG gated PET, # and % | 61% | 12% | 70% | 10% | <0.00001 |
| Relative rest, % of LV < 60% of maximum – average | 7% | ±10% | 4% | ±10% | 0.001 |
| Relative stress, % of LV < 60% of maximum – average | 28% | ±18% | 5% | ±10% | <0.00001 |
| CFC severe, % of LV – average   | 18% | ±21% | 2% | ±8% | <0.00001 |
| CFC severe, % of LV – median    | 12% | 0%    |       |       |     |
| Mild CFC > 15% of LV, # and %  | 116 | 87%     | 1,556 | 43%    | <0.00001 |
| Moderate CFC > 15% of LV, # and % | 37 | 28% | 222 | 6% | <0.00001 |
| Severe CFC > 0% of LV, # and % | 108 | 81% | 616 | 17% | <0.00001 |
| Minimum quadrant average CFR    | 1.436 ± 0.592 | 2.39 | ±0.69 | <0.00001 |
| Minimum quadrant average stress flow (cc/min/g) | 0.968 | ±0.463 | 1.84 | ±0.66 | <0.00001 |
| Minimum quadrant CFR < 2.0, # and % | 109 | 81% | 616 | 17% | <0.00001 |
| Global average CFR              | 1.91 | ±0.63 | 2.60 | ±0.70 | <0.00001 |
| Global average stress flow (cc/min/g) | 1.36 | ±0.50 | 2.05 | ±0.66 | <0.00001 |
| Stress flow maximum (cc/min/g)  | 2.25 | ±0.65 | 2.73 | ±0.76 | <0.00001 |
| CFR maximum                     | 3.20 | ±0.98 | 3.65 | ±1.00 | <0.00001 |

ACEI = angiotensin-converting enzyme inhibitors; ARB = angiotensin receptor blockers; EF = ejection fraction; HU = Hounsfield units.
fewer than 90 d, which is considered too short a follow-up time for meaningful outcomes, leaving 3,774 PET scans for this analysis. As a tertiary care center, our cohort had a high prevalence of CAD and symptoms or multiple risk factors shown in Table 1 for PET groups with and without revascularization within 90 d after PET.

**Cardiac PET Acquisition**

As described previously, subjects were instructed to fast for 4 h and abstain from caffeine and cigarettes for 24 h. Cardiac PET images were acquired using a Discovery ST 16-slice PET/CT scanner (GE Healthcare) in 2-dimensional mode; standard vasodilator stress, primarily dipyridamole, and 1,110–1,850 MBq (30–50 mCi) of $^{82}$Rb (Bracco Diagnostics); and attenuation correction by cine CT with reduced radiation dose, correct coregistration, and optimal region-of-interest placement for arterial input (3–5).

**Cardiac PET Analysis**

Absolute myocardial perfusion in cc/min/g was quantified for each of 1,344 pixels of the left ventricle (LV) images using validated HeartSee software (University of Texas Health Science Center—Houston, Food and Drug Administration [FDA]–approved K171303) (3–5) with a methodology precision of ±10% (coefficient of variance) on serial rest–rest and stress–stress images in the same patient minutes apart under stable physiologic conditions (5). As requested and expected by referring physicians, every Cardiac PET Consultation Report provides integrated synthesis of all clinical, visual, and quantitative PET metrics as favoring coronary angiography, revascularization for specific coronary artery distributions, or medical management alone depending on clinical judgment of referring physician.

**Coronary Flow Reserve (CFR), Stress Perfusion, and Coronary Flow Capacity (CFC)**

PET perfusion was quantified by automated, objective, size–severity measurements. CFR was computed as stress-to-rest ratio for each of 1,344 pixels. Pixel values of rest–stress relative images, quantitative perfusion, and CFC comprise infinite numbers of values and combinations reflecting true perfusion heterogeneity that require compressing into essential clinically relevant ranges and regional distribution for clinical utility (3–5). Accordingly, the CFC map in Figure 1 color codes each pixel within 5 color ranges for combined CFR and stress perfusion values of each pixel, spatially maps each pixel back into its LV location with corresponding stress perfusion and CFR values, and calculates percentage of LV for each range of combined both CFR and stress perfusion values listed in the CFC color histogram bar.

Figure 1 also illustrates precise, artery-specific, regional size and severity of perfusion abnormalities summarized for this example in the “Results” section. The objective basis for the color-coded CFC plot is detailed in Supplemental Figure 1 (supplemental materials are available at http://jnm.snmjournals.org) as approved by FDA K171303 (3–5), including CFC maps with any pixels coded blue defined as both CFR ≤ 1.27 and stress perfusion ≤ 0.83 that for simplicity is called CFCsevere expressed as percentage of LV.

**Clinical Follow-up**

As approved by our Committee For Protection of Human Subjects, prospective programmed follow-up is obtained after every PET scan systematically and continuously by a trained masked research assistant for all-cause death, MI, stroke, first or repeat percutaneous intervention (PCI), or coronary artery bypass grafting (CABG) from clinic or hospital records, mailed questionnaires, phone calls, email, or web searches of newspaper obituaries as an ongoing monthly routine, repeated 3 times for initial nonresponders.

Outcomes are all-cause death alone, combined death/MI/stroke (DMS), and major adverse cardiovascular events (MACE) defined as DMS and revascularization (PCI or CABG), obtained and adjudicated by experienced research assistants, research nurses, and cardiologists masked to PET data. All-cause mortality was analyzed to avoid death misclassification bias.
Stroke was included due to its risk during procedures and its association with the course of atherosclerosis. Revascularization (PCI or CABG) within 90 d after PET was considered as guided by PET. As customary in the literature, fewer than 90 d of event-free follow-up is too short for useful follow-up outcomes after revascularization. Follow-up was obtained for 95% of PET scans at up to 9 y, mean 3.0 ± 2.3 y, with 134 PET scans associated with revascularization (PCI/CABG), 132 associated with death, 56 surviving associated with MI, or 51 associated with stroke.

Statistical Analysis
We used SAS 9.4 (SAS Institute, Inc.) for multiple Cox regression modeling of covariates of PET metrics plus other clinical characteristics for association with time to first composite MACE (PCI/CABG, DMS) or DMS or all-cause death. We performed collinearity analysis of perfusion measurements before estimation of parameters in final models using clinically guided search of covariates starting with a basic standard risk-factor model for predicting time to first event of MACE, DMS, or death alone.

The second covariate variable group included simple relative objective size and severity of relative perfusion abnormalities as percentage of LV and coronary calcium on CT scan for attenuation correction classified by OsirIX (Pixmeo SARL). The third covariate variable group included all quantitative perfusion metrics. Multiple Cox regression modeling with time-varying covariates was also used to assess effects of revascularization (PCI/CABG) within 90 d after PET as an explanatory variable on subsequent DMS compared with all other clinical and PET characteristics.

Hazard ratios for revascularization versus no revascularization were plotted over time with covariates set to their median values. We used 2-tailed tests and \( P < 0.05 \) as an indication of statistical significance of rejecting the null hypothesis of null effects. Analysis was performed on a per-scan and per-patient basis with time-varying covariates for outcomes after each PET at different times in the same patient or for different patients.

For significance of discrete variables we used the \( \chi^2 \) test, and for continuous variables we used an unpaired \( t \) test with unequal variance between groups. For comparing survival curves, we plotted Kaplan–Meier plots and used log-rank test. As additional independent covariates for Cox regression modeling, we added the interaction of CFC severe with revascularization on all-cause death and the propensity score (6) of undergoing PCI/CABG within 90 d that was estimated by logistic regression analysis with the following covariates: male, age, hypertension, diabetes, smoking, dyslipidemia, MI within 3 mo, MI > 3 mo prior, PCI, CABG, coronary calcium, prior abnormal angiogram, stress ejection fraction, resting minimum quadrant average relative severity, vasodilator stress angina or ST > 1 mm depression, clinical angina, taking statin, aspirin, antiplatelet, nitrate, insulin, hypoglycemic, \( \beta \)-blocker, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, or diuretic medications.

RESULTS
Example of Artery-Specific Regional Quantitative PET Perfusion
Since regional precision of quantitative PET may not be widely familiar, Figure 1 illustrates a 59-y-old marathon runner with hyperlipidemia, hypertension, and family history of CAD who had early morning ventricular fibrillation, CPR by his wife, defibrillation by a 911 team, and ST elevation MI with thrombus in the patent left anterior descending coronary artery (LAD) that was stented as the culprit artery. Because of recurrent angina, rest–stress PET was performed, showing a small, severe, nontransmural scar (dark green within an area demarked by dashed white lines) comprising 5% of the LV in the first diagonal distribution.

A border zone of less severe nontransmural scarring (lighter green) comprised another 7% of LV. Average rest perfusion within the rest defect was 0.5 cc/min/g compared with typical 0.25 cc/min/g for transmural scarring. Size and location of the resting scar indicated that the culprit artery for ventricular fibrillation arrest and MI was an occluded first diagonal and not LAD, which was reasonably stented under emergency circumstances as the most accessible without this PET image of the infarcted region in a diagonal distribution or recognition of a flush occlusion of the diagonal branch.

With dipyridamole stress, the rest perfusion defect was larger and more severe, comprising 36% of LV, indicating a large first diagonal branch as the source of angina, whereas LAD distribution showed excellent CFC throughout the septum and apex with no scar. On the basis of PET-quantified extent, severity, and artery-specific location of the original MI and source of recurrent angina, a repeated angiogram showed the culprit subtotal occlusion of the diagonal branch (inset Fig. 1) that was opened with a double balloon procedure (inset) through the mesh of the LAD stent (inset) with

![Figure 2](image-url)
resulting patency of the first diagonal (inset) and resolution of angina.

**MACE and Combined CFR and Stress Perfusion (CFC)**

Kaplan–Meier plots in Figure 2A show high MACE (death, MI, stroke, PCI, or CABG) associated with CFC severe defined as pixels having both CFR ≤ 1.27 and stress perfusion ≤ 0.83 cc/min/g (blue) cumulatively expressed as percentage of LV by automated, objective, software. Even small blue regions typically have large moderately severe border zones (green). However, in Figure 2A, PET scans with no severe CFC (no blue) associate with low MACE, a significant difference.

Kaplan–Meier plots in Figure 2B show high risk of DMS associated with CFC severe (blue) whereas PET scans with no severely reduced CFC (no blue) associated with low risk of DMS, also a significant difference.

In Table 2, multiple Cox regression modeling shows significant association of CFC severe, revascularization within 90 d after PET,

### Table 2

| Parameter                        | P      | Hazard ratio | 95% hazard ratio confidence limit |
|----------------------------------|--------|--------------|----------------------------------|
| Sex (male)                       | 0.3032 | 1.21         | 0.842–1.738                      |
| Age (y)                          | <0.0001| 1.046        | 1.03–1.062                       |
| Hypertension                     | 0.4178 | 1.14         | 0.83–1.568                       |
| Diabetes                         | 0.0013 | 1.627        | 1.21–2.188                       |
| Dyslipidemia                     | 0.4291 | 0.793        | 0.446–1.41                       |
| MI distant > 3 mo                | 0.3159 | 1.195        | 0.844–1.691                      |
| MI recent < 3 mo                 | 0.9883 | 0.993        | 0.365–2.698                      |
| Prior PCI                        | 0.0069 | 1.507        | 1.119–2.028                      |
| Prior CABG                       | 0.5423 | 1.107        | 0.798–1.535                      |
| Coronary calcium                 | 0.2948 | 1.474        | 0.713–3.049                      |
| Relative stress MQA              | 0.073  | 0.984        | 0.966–1.002                      |
| Stress flow MQA                  | 0.0032 | 1.016        | 1.005–1.027                      |
| CFR MQA                          | 0.7462 | 0.943        | 0.663–1.342                      |
| CFC severe (blue)                | 0.0098 | 0.65         | 0.469–0.901                      |
| PCI/CABG within 90 d             | 0.0396 | 0.552        | 0.313–0.972                      |

MQA = minimum quadrant average for each perfusion metric in the distribution of each coronary artery.
and reduced hazard of DMS by approximately 45% versus no revascularization ($P = 0.0396$). With time-dependent covariates (Supplemental Table 1), DMS was reduced by 54% ($P = 0.0477$).

To avoid bias in adjudication of cause of death or MI, Table 3 shows CFCsevere and revascularization within 90 d after PET associated with reduced hazard of all-cause death by 60% compared with no revascularization ($P = 0.0159$).

Table 4 shows a significant interaction of CFCsevere and PCI or CABG within 90 d after PET with death (CFCsevere*pcicabg90, $P = 0.003$) thereby validating all-cause mortality as predominantly coronary deaths (Supplemental Fig. 2 provides an additional graph of this interaction). The propensity score and the interaction of CFCsevere with PCI/CABG within 90 d after PET as covariates in the Cox regression model are also shown in Table 4. Table 4 confirms the significantly reduced death in the revascularization group ($P = 0.036$) but also significant residual risk of death ($P = 0.0007$) despite revascularization and significantly more intense medical treatment (Table 1), consistent with more severe, larger relative and quantitative PET perfusion abnormalities with more diffusely reduced PET metrics than no-revascularization group (Table 1).

The single-view PET images of Figure 3 illustrate the range of severe high-risk CFC (blue) and of mild to moderate low-risk CFC (no blue), all with coronary calcification or documented CAD as examples for outcomes in Figures 2 and 4.

Figure 4 displays these outcomes graphically as hazard ratios showing reduced DMS after revascularization within 90 d after PET (solid blue line) versus no revascularization within 90 d after PET (solid red line) ($P = 0.0396$). For less severe CFC abnormalities (no blue) consisting of mild or moderate CFC impairment, DMS were significantly higher or worse in the revascularization (blue dashed line) versus no-revascularization groups (red dashed line) ($P = 0.45$).

### PET Metrics Associated with Revascularization and No Revascularization

In Table 1, the PET group with revascularization had significantly worse risk factors, more prior coronary events and procedures, more intense medical treatment, more angina, lower ejection fraction, and substantially more severe, larger relative and quantitative PET perfusion abnormalities with more diffusely reduced PET metrics than no-revascularization group.

| Parameter                               | $P$     | Hazard ratio | 95% hazard ratio confidence limit |
|-----------------------------------------|---------|--------------|----------------------------------|
| Sex (male)                              | 0.7392  | 1.123        | 0.566–2.23                       |
| Age (y)                                 | <0.0001 | 1.074        | 1.041–1.107                      |
| Hypertension                            | 0.4254  | 1.285        | 0.694–2.381                      |
| Diabetes                                | 0.0318  | 1.763        | 1.051–2.957                      |
| Dyslipidemia                            | 0.9919  | 0.995        | 0.366–2.707                      |
| MI distant > 3 mo                       | 0.4416  | 1.262        | 0.698–2.281                      |
| MI recent < 3 mo                        | 0.886   | 1.113        | 0.258–4.808                      |
| Prior PCI                               | 0.5981  | 0.869        | 0.516–1.464                      |
| Prior CABG                              | 0.2059  | 1.428        | 0.822–2.478                      |
| Coronary calcium                        | 0.5926  | 1.739        | 0.229–13.207                     |
| Relative stress MQA                     | 0.5599  | 0.99         | 0.959–1.023                      |
| Stress flow MQA                         | 0.2598  | 0.664        | 0.326–1.354                      |
| CFR MQA                                 | 0.4168  | 0.777        | 0.423–1.429                      |
| CFC severe (blue)                       | 0.0194  |              |                                  |
| PCI/CABG within 90da                    | 0.0355  |              |                                  |
| CFCsevere*pcicabg90                     | 0.003   |              |                                  |
| Propensity score                        | 0.0007  | 12.619       | 2.891–55.08                      |

MQA = minimum quadrant average for each perfusion metric in the distribution of each coronary artery.
For all severely reduced CFC (blue), the histogram of severity–size distribution in the LV was substantially worse in the group with revascularization within 90 d after PET than in the nonrevascularized group by the Kolmogorov–Smirnov statistic (0.39, \( P < 0.0001 \)).

In Table 5, after CFCsevere (blue) was excluded as a covariate in the Cox analysis, other PET metrics alone, including CFCmoderate (green), regional or global CFR, stress perfusion, or relative stress defects, did not associate significantly with reduced DMS after revascularization, reflecting suboptimal selection for benefit from revascularization (Supplemental Tables 2 and 3). Although stress perfusion and CFR alone also failed to associate with reduced DMS, their combination in CFCsevere was significantly associated with decreased DMS after revascularization (\( P = 0.0396 \), Fig. 3, Tables 2–4) due to CFC accounting for heterogeneity unrelated to stenosis or diffuse CAD severity.

In Supplemental Table 4, compared with the revascularization group, the 616 PET scans with CFCsevere not followed by revascularization within 90 d after PET had smaller stress defects and CFC abnormalities, less coronary calcium, higher global and regional CFR and stress perfusion, less clinical angina, less angina or ST depression with PET stress (all with \( P < 0.00001 \) for Supplemental Table 4), and comparable risk factors. These less severe variables combined with the referring physicians’ clinical decision may explain their lack of revascularization. However, this nonrevascularized group with smaller abnormalities and less angina had higher risk of DMS and all-cause death than the group with more severe, larger perfusion abnormalities undergoing revascularization (\( P = 0.0396 \); Fig. 4; Tables 2–4).

The predictive value of regional CFC incorporating regional CFR and regional stress perfusion versus the failure of global CFR or global stress perfusion to associate with reduced DMS after revascularization within 90 d after PET was largely due to regional perfusion heterogeneity (3–5) as illustrated in Figure 5. Three different clinical examples provide clear conceptual physiologic insight on different kinds of heterogeneity commonly seen that explain these statistical outcomes having important clinical impact for personalized artery-specific interventional decisions. As an example, Figure 5A illustrates why global CFR is a poor guide to patient management since global CFR may be good at 2.7, which fails to account for a large, high-risk, severe, stress perfusion abnormality with severely reduced regional CFR that is averaged out in global CFR by high CFR in areas surrounding the severe regional stress defect.

As additional examples, resting perfusion heterogeneity and hence CFR heterogeneity (3–5) may cause apparently low global (Fig. 5B) or regional abnormal CFR (Fig. 5C) due to resting flow heterogeneity but with high global or regional stress perfusion that is accounted for by normal CFC associated with low risk. This CFR heterogeneity due to heterogeneous resting perfusion is so common that it reduces statistical strength of association between CFR alone and decreased DMS after revascularization.

**DISCUSSION**

Regional CFC integrating regional CFR and regional absolute stress perfusion in cc/min/g per pixel provide regional, artery-specific, objective size–severity quantification associated with high risk of death, MI and stroke independently of standard risk factors and other quantitative PET metrics. For severely reduced CFC, coronary revascularization within 90 d after PET is associated with reduced hazard of death, MI, and stroke by approximately 50% compared with severely abnormal perfusion without revascularization within 90 d after PET or for revascularization of moderate to mild perfusion abnormalities. The flip side of this data is a corresponding reduction in invasive procedures having no benefit for reducing death or MI in randomized trials.

**Comparison to the Literature**

Since the first author originated concepts of CFR for defining physiologic stenosis severity in 1974, pharmacologic stress perfusion imaging in 1978, PET imaging for coronary stenosis in

**TABLE 5**

| PET metric                                      | \( P \) |
|------------------------------------------------|---------|
| Coronary flow capacity severe \% of LV (blue)  | 0.0396  |
| Coronary flow capacity moderate \% of LV (green) | 0.4     |
| Minimum quadrant average stress perfusion cc/min/g (no CFC) | 0.32    |
| Minimum quadrant coronary flow reserve (no CFC) | 0.08    |
| Global average stress perfusion cc/min/g (no CFC) | 0.45    |
| Global coronary flow reserve (no CFC) | 0.45    |
| Relative stress defect (\% LV < 60% of maximum activity - no CFC) | 0.25    |
Global perfusion measurements fail to account for severe regional perfusion abnormalities or for resting perfusion heterogeneity with corresponding heterogeneity of CFR. Adequate global CFR of 2.8 that fails to account for severe regionally reduced CFR due to high CFR in rest of LV. Despite adequate global CFR, severely reduced regional CFR associates with high risk of MACE. Single anterior views of high stress perfusion in cc/min/g with low CFR of 1.8 due to high resting perfusion that is accounted for by normal CFC map associated with low CV risk. Single inferior views of heterogeneous high resting and high stress perfusion causing apparent severe regional low CFR alone that is accounted for by low-risk normal CFC map.

This study had limitations. This study analyzes a nonrandomized, single-center, large clinical cohort by multivariate Cox regression and propensity modeling for adverse outcomes with and without revascularization. Our data provide a scientific basis for PET facilities using other protocols, radionuclides, or scanners documenting comparable reproducibility and severity thresholds for their own PET protocols in cardiology, nuclear medicine, or radiology. Alternatively, PET sites can use the same protocols and FDA-approved software with specific flow models for both Rb and N-ammonia with its 3,774 case database for CFC maps accessible on the FDA website.

Our observations suggest that failure of randomized revascularization trials to reduce MI and death may be due in part to lack of objective size–severity quantitative perfusion abnormalities. Future interventional trials may benefit from integrated regional quantitative myocardial perfusion for assessing effects of revascularization on event-free survival. However, it may be difficult to randomize patients with large severe PET defects associated with high mortality or morbidity associated with reduced by revascularization.

CONCLUSION

CFC integrating regional CFR and regional absolute stress perfusion in cc/min/g by PET provides automated, objective, artery-specific, regional size–severity, physiologic quantification associated with high risk of death and MI that is reduced by 54% after revascularization not seen for revascularization of moderate and mild perfusion abnormalities or for medical treatment alone or for other PET metrics.

DISCLOSURE

K. Lance Gould received internal funding from the Weatherhead PET Center and is the 510(k) applicant for FDA-approved HeartSee K171303 PET software. To avoid any conflict of interest, K. Lance Gould assigned any royalties arising from PET software to University of Texas for research or student scholarships. Nils P. Johnson received internal funding from the Weatherhead PET Center, has an institutional licensing and consulting agreement with Boston Scientific for the smart minimum FFR algorithm, and received institutional research support from St. Jude Medical (for NCT02184117) and Volcano/Philips Corporation (for NCT02328820), makers of intracoronary pressure and flow sensors. No other potential conflict of interest relevant to this article was reported.

REFERENCES

1. van Nunen LX, Zimmermann FM, Tonino PAL, et al. Fractional flow reserve versus angiography for guidance of PCI in patients with multivessel coronary artery disease (FAME): 5-year follow-up of a randomized controlled trial. Lancet. 2015;386:1853–1860.
2. De Bruyne B, Baudhuin T, Melin JA, et al. Coronary flow reserve calculated from pressure measurements in humans: validation with positron emission tomography. Circulation. 1994;89:1013–1022.
3. Gould KL, Johnson NP, Bateman TM, et al. Anatomic versus physiologic assessment of coronary artery disease: role of CFR, FFR, and PET imaging in revascularization decision-making. J Am Coll Cardiol. 2013;62:1639–1653.
4. Johnson NP, Gould KL. Integrating noninvasive absolute flow, coronary flow reserve, and ischemic thresholds into a comprehensive map of physiologic severity. JACC Cardiovasc Imaging. 2012;5:430–440.
5. Kikianyan D, Johnson NP, Roby AE, Patel MB, Kirkeeide R, Gould KL. Routine clinical quantitative rest stress myocardial perfusion for managing coronary artery disease: clinical relevance OTRV. JACC Cardiovasc Imaging. 2017;10:565–577.
6. Haakko JS, Lewis RJ. The propensity score. JAMA. 2015;314:1637–1638.
7. Gupta A, Taqueti VR, van de Hoef TP, et al. Integrated non-invasive physiological assessment of coronary circulatory function and impact on cardiovascular mortality in patients with stable coronary artery disease. Circulation. 2017;136:2325–2336.